SCHEMBL5377067

SCHEMBL5377067

CC(C)(C)OC(=O)NCCCOc1ccc(Cl)cc1[N+](=O)[O-]

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 2/20 0.49
S1PR4 O95977 1/20 0.49
ALDH1A1 P00352 9/20 0.48
IDO1 P14902 2/20 0.48
CA12 O43570 2/20 0.47
CA1 P00915 2/20 0.47
CA2 P00918 2/20 0.47
CA9 Q16790 2/20 0.47
SMN1; SMN2 Q16637 5/20 0.46
KDM4E B2RXH2 4/20 0.46
KMT2A Q03164 3/20 0.46
NPC1 O15118 1/20 0.46
HTT P42858 1/20 0.45
MAPT P10636 4/20 0.45
GAA P10253 2/20 0.45
MEN1 O00255 2/20 0.45
CYP1A2 P05177 1/20 0.45
CYP3A4 P08684 1/20 0.45
CYP2D6 P10635 1/20 0.45
CYP2C9 P11712 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16123203 0.87 ALDH1A1 (0.48) RAB9AALDH1A1CA12CA1CA2
SCHEMBL19175184 0.84 CA12 (0.47) RAB9AALDH1A1CA12CA1CA2
SCHEMBL14660487 0.83 TP53 (0.57) RAB9AS1PR4ALDH1A1IDO1CA12
SCHEMBL6261344 0.82 ALDH1A1 (0.51) RAB9AALDH1A1CA12CA1CA2
SCHEMBL4573884 0.81 CA12 (0.51) ALDH1A1IDO1CA12CA1CA2
SCHEMBL3452611 0.81 MAPT (0.54) RAB9AALDH1A1CA12CA1CA2
SCHEMBL7434383 0.80 ALDH1A1 (0.56) RAB9AALDH1A1IDO1CA12CA1
SCHEMBL6260157 0.80 MAPT (0.53) RAB9AALDH1A1CA12CA1CA2
SCHEMBL360813 0.80 RAB9A (0.60) RAB9AALDH1A1IDO1CA12CA1
SCHEMBL3453194 0.80 IDO1 (0.60) RAB9AS1PR4ALDH1A1IDO1CA12

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7202244-B2 Chk-1 inhibitors MILLENNIUM PHARMACEUTICALS, INC. (US) 2007-04-10 US disclosed
US-20050176733-A1 Chk-1 inhibitors MILLENNIUM PHARMACEUTICALS, INC. (US) 2005-08-11 US disclosed
WO-2005072733-A1 DYARYLUREA COMPOUNDS AS CHK-1 INHIBITORS MILLENNIUM PHARMACEUTICALS, INC. (US) 2005-08-11 WO disclosed
US-20040014765-A1 Chk-1 inhibitors MILLENNIUM PHARMACEUTICALS, INC. 2004-01-22 US disclosed
WO-2003101444-A1 DIARYLUREA COMPOUNDS AND DERIVATIVES AS CHK-1 INHIBITORS FOR THE TREATMENT OF CANCER MILLENNIUM PHARMACEUTICALS, INC. (US) 2003-12-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040014765-A1 Chk-1 inhibitors CHKA, CHKB, CHEK1 RAB9A 3026/4885S1PR4 1658/4885ALDH1A1 4635/4885
US-20050176733-A1 Chk-1 inhibitors CHEK1, CHEK2, CHKA RAB9A 2714/4885S1PR4 2110/4885ALDH1A1 3770/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.